Cancers of unknown primary site: ESMO clinical recommendation for diagnosis, treatment and follow-up.

نویسندگان

  • E Briasoulis
  • N Pavlidis
  • E Felip
چکیده

Cancers of unknown primary site: ESMO Clinical Recommendation for diagnosis, treatment and follow-up E. Briasoulis, N. Pavlidis & E. Felip On behalf of the ESMO Guidelines Working Group* Department of Medical Oncology, University of Ioannina, Ioannina Ipiros, Greece; Department of Medical Oncology, University of Ioannina, Ioannina Ipiros, Greece; Medical Oncology Service, Vall d’Hebron University Hospital, Barcelona, Spain

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Cancers of unknown primary site: ESMO clinical recommendations for diagnosis, treatment and follow-up.

Immunohistochemistry should be applied in poorly differentiated cases to exclude chemosensitive and potentially curable tumors (i.e. lymphomas and germ cell tumors). If diagnosis is adenocarcinoma, immunostaining for prostate-specific antigen (PSA) in male patients and for estrogen and progesterone receptors in females with axillary node metastases is advisable to rule out hormone-sensitive tum...

متن کامل

Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

K. Fizazi1, F. A. Greco2, N. Pavlidis3, G. Daugaard4, K. Oien5 & G. Pentheroudakis3, on behalf of the ESMO Guidelines Committee* Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Tennessee Oncology, Centennial Medical Center, Nashville, USA; Department of Medical Oncology, University of Ioannina, Ioannina, Greece; Department of Oncology 5073, Ri...

متن کامل

Clinical utility of gene-expression profiling for tumor-site origin in patients with metastatic or poorly differentiated cancer: impact on diagnosis, treatment, and survival

PURPOSE The primary tissue-site origin in over 4% of cancers remains uncertain despite thorough clinicopathological evaluation. This study assessed the effect of a Food and Drug Administration-cleared 2,000- gene-expression-profiling (GEP) test on primary tissue-site working diagnoses and management for metastatic and poorly differentiated cancers. METHODS Clinical information was collected f...

متن کامل

Advanced colorectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.

Rectal cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up B. Glimelius & J. Oliveira On behalf of the ESMO Guidelines Working Group* Department of Oncology, Radiology and Clinical Immunology, University Hospital, Uppsala and Department of Oncology and Pathology, Karolinska Institute, Stockholm, Sweden; Service of Medical Oncology, Portuguese Institute of Oncology, Lisb...

متن کامل

Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up A. Okines, M. Verheij, W. Allum, D. Cunningham & A. Cervantes On behalf of the ESMO Guidelines Working Group* GI Clinical Trials Unit, Royal Marsden Hospital, Sutton, UK; Department of Radiation Oncology and Division of Cellular Biochemistry, The Netherlands Cancer Institute—Antoni van Leeuwenhoek Hospital,...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Annals of oncology : official journal of the European Society for Medical Oncology

دوره 19 Suppl 2  شماره 

صفحات  -

تاریخ انتشار 2008